Shopping Cart
- Remove All
- Your shopping cart is currently empty
SB-200646A is an orally active, selective antagonist of 5-HT2B/2C over 5-HT2A receptor with pKi of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A exerts anxiolytic and electrophysiological properties in vivo.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $35 | 5 days | |
1 mL x 10 mM (in DMSO) | $76 | 5 days |
Description | SB-200646A is an orally active, selective antagonist of 5-HT2B/2C over 5-HT2A receptor with pKi of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A exerts anxiolytic and electrophysiological properties in vivo. |
In vitro | SB200646A (4 μM) eliminates the increase in miniature inhibitory postsynaptic current (mIPSC) frequency induced by ethanol, without affecting the basal mIPSC frequency. |
In vivo | SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons. Intravenous administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and percentage of events as bursts in spontaneously active VTA dopaminergic neurons and increases the percentage of events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons[1]. |
Molecular Weight | 302.76 |
Formula | C15H15ClN4O |
Cas No. | 143797-62-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 225 mg/mL (743.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.